<DOC>
	<DOCNO>NCT02595073</DOCNO>
	<brief_summary>Efficacy Safety DSXS ( Taro Pharmaceuticals , U.S.A. , Inc. ) Patients Moderate Severe Atopic Dermatitis</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety DSXS With Atopic Dermatitis</brief_title>
	<detailed_description>A Randomized , Double-Blind , Placebo-Controlled , Parallel-Design , Multiple-Site Clinical Study Evaluate Efficacy Safety DSXS ( Taro Pharmaceuticals , U.S.A. , Inc. ) Patients Moderate Severe Atopic Dermatitis</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>male nonpregnant female , age 6 month old , confirm diagnosis moderate severe AD Lacks stable diagnosis atopic dermatitis diagnose mild atopic dermatitis .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>